Articles related to VISION LOSS

The American Academy of Ophthalmology updated hydroxychloroquine retinopathy screening recommendations, emphasizing dose limits, OCT and FAF as primary screening modalities, and risk stratification by renal status and concurrent tamoxifen use.

A phase 3 head-to-head RCT of 689 patients found intravitreal brolucizumab preserved visual acuity at 54 weeks while panretinal photocoagulation patients lost a mean of approximately 4 letters, though intraocular inflammation rates were higher with brolucizumab.

Vigabatrin can cause irreversible peripheral retinal toxicity that is often asymptomatic, underscoring the need for consistent ophthalmic monitoring in treated patients.

“The increased risk of NAION with Wegovy is due to the higher dosage of semaglutide…the difference between the two dosages and the rates of NAION may indicate a dose-dependent increase in risk.” – Benjamin Bert, MD

More than 80% of the patients were able to read letters and words, and some of them are reading pages in a book.

Patients taking semaglutide for diabetes were more than four times more likely to develop NAION compared to those on other diabetes medications, while those using it for obesity had a seven-fold increased risk.